Himerni antigenski receptor (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Himerni antigenski receptor" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

23nih.gov

4^th place

8^th place

14doi.org

2^nd place

5^th place

2fda.gov

447^th place

409^th place

2europa.eu

68^th place

28^th place

2semanticscholar.org

11^th place

51^st place

1nytimes.com

7^th place

37^th place

1medpagetoday.com

9,274^th place

low place

1businesswire.com

615^th place

3,307^th place

1labiotech.eu

low place

1clinicaltrials.gov

5,225^th place

4,764^th place

businesswire.com

»U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma«. www.businesswire.com. 5. februar 2021. Pridobljeno 5. februarja 2021.

clinicaltrials.gov

»Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)«. ClinicalTrials.gov. Pridobljeno 21. februarja 2018.

doi.org

Jacobson CA, Ritz J (november 2011). »Time to put the CAR-T before the horse«. Blood. 118 (18): 4761–2. doi:10.1182/blood-2011-09-376137. PMID 22053170.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Kochenderfer, in sod. (2010). »Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. 2010«. Blood. 116 (20): 4099–102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer, in sod. (2015). »Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor«. Journal of Clinical Oncology. 2015 (33): 540–9. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Schultz L, Mackall C (2019). »Driving CAR T cell translation forward«. Science Translational Medicine. 11 (481): eaaw2127. doi:10.1126/scitranslmed.aaw2127. PMID 30814337.
Lim WA, June CH (Februar 2017). »The Principles of Engineering Immune Cells to Treat Cancer«. Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, in sod. (Februar 2020). »Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice«. Gastroenterology. 158 (8): 2250–2265.e20. doi:10.1053/j.gastro.2020.02.011. PMID 32060001.
Yu JX, Hubbard-Lucey VM, Tang J (30. maj 2019). »The global pipeline of cell therapies for cancer«. Nature Reviews Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Almåsbak H, Aarvak T, Vemuri MC (2016). »CAR T Cell Therapy: A Game Changer in Cancer Treatment«. Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (september 2017). »Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts«. EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). »Toxicity and management in CAR-T cell therapy«. Molecular Therapy Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Breslin S (Februar 2007). »Cytokine-release syndrome: overview and nursing implications«. Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.
Brudno JN, Kochenderfer JN (Junij 2016). »Toxicities of chimeric antigen receptor T cells: recognition and management«. Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (Junij 2016). »CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients«. The Journal of Clinical Investigation. 126 (6): 2123–38. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Makita S, Yoshimura K, Tobinai K (Junij 2017). »Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma«. Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.

europa.eu

ema.europa.eu

https://www.ema.europa.eu/medicines/human/EPAR/kymriah, vpogled: 14. 10. 2018.
https://www.ema.europa.eu/medicines/human/EPAR/yescarta, vpogled: 14. 10. 2018.

fda.gov

»BLA 125646 Tisagenlecleucel - Novartis Briefing document to FDA ODAC« (PDF).
»FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma«. FDA. Pridobljeno 14. oktobra 2018.

labiotech.eu

»A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology« (tiskovna objava). labiotech. 8. marec 2018. Pridobljeno 19. aprila 2018.

medpagetoday.com

Thumbs Up to Latest CAR-T cell Approval - New era for lymphoma, leukemia, possibly other cancers. Oktober 2017

nih.gov

pubmed.ncbi.nlm.nih.gov

Jacobson CA, Ritz J (november 2011). »Time to put the CAR-T before the horse«. Blood. 118 (18): 4761–2. doi:10.1182/blood-2011-09-376137. PMID 22053170.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Kochenderfer, in sod. (2010). »Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. 2010«. Blood. 116 (20): 4099–102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer, in sod. (2015). »Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor«. Journal of Clinical Oncology. 2015 (33): 540–9. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Schultz L, Mackall C (2019). »Driving CAR T cell translation forward«. Science Translational Medicine. 11 (481): eaaw2127. doi:10.1126/scitranslmed.aaw2127. PMID 30814337.
Lim WA, June CH (Februar 2017). »The Principles of Engineering Immune Cells to Treat Cancer«. Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, in sod. (Februar 2020). »Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice«. Gastroenterology. 158 (8): 2250–2265.e20. doi:10.1053/j.gastro.2020.02.011. PMID 32060001.
Yu JX, Hubbard-Lucey VM, Tang J (30. maj 2019). »The global pipeline of cell therapies for cancer«. Nature Reviews Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Almåsbak H, Aarvak T, Vemuri MC (2016). »CAR T Cell Therapy: A Game Changer in Cancer Treatment«. Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (september 2017). »Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts«. EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). »Toxicity and management in CAR-T cell therapy«. Molecular Therapy Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Breslin S (Februar 2007). »Cytokine-release syndrome: overview and nursing implications«. Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.
Brudno JN, Kochenderfer JN (Junij 2016). »Toxicities of chimeric antigen receptor T cells: recognition and management«. Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (Junij 2016). »CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients«. The Journal of Clinical Investigation. 126 (6): 2123–38. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Makita S, Yoshimura K, Tobinai K (Junij 2017). »Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma«. Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.

ncbi.nlm.nih.gov

Kochenderfer, in sod. (2010). »Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. 2010«. Blood. 116 (20): 4099–102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
Kochenderfer, in sod. (2015). »Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor«. Journal of Clinical Oncology. 2015 (33): 540–9. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
Lim WA, June CH (Februar 2017). »The Principles of Engineering Immune Cells to Treat Cancer«. Cell. 168 (4): 724–740. doi:10.1016/j.cell.2017.01.016. PMC 5553442. PMID 28187291.
Almåsbak H, Aarvak T, Vemuri MC (2016). »CAR T Cell Therapy: A Game Changer in Cancer Treatment«. Journal of Immunology Research. 2016: 5474602. doi:10.1155/2016/5474602. PMC 4889848. PMID 27298832.
Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (september 2017). »Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts«. EMBO Molecular Medicine. 9 (9): 1183–1197. doi:10.15252/emmm.201607485. PMC 5582407. PMID 28765140.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). »Toxicity and management in CAR-T cell therapy«. Molecular Therapy Oncolytics. 3: 16011. doi:10.1038/mto.2016.11. PMC 5008265. PMID 27626062.
Brudno JN, Kochenderfer JN (Junij 2016). »Toxicities of chimeric antigen receptor T cells: recognition and management«. Blood. 127 (26): 3321–3330. doi:10.1182/blood-2016-04-703751. PMC 4929924. PMID 27207799.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (Junij 2016). »CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients«. The Journal of Clinical Investigation. 126 (6): 2123–38. doi:10.1172/JCI85309. PMC 4887159. PMID 27111235.
Makita S, Yoshimura K, Tobinai K (Junij 2017). »Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma«. Cancer Science. 108 (6): 1109–1118. doi:10.1111/cas.13239. PMC 5480083. PMID 28301076.

nytimes.com

F.D.A. Approves Second Gene-Altering Treatment for Cancer 2017

semanticscholar.org

api.semanticscholar.org

Yu JX, Hubbard-Lucey VM, Tang J (30. maj 2019). »The global pipeline of cell therapies for cancer«. Nature Reviews Drug Discovery. 18 (11): 821–822. doi:10.1038/d41573-019-00090-z. PMID 31673124. S2CID 190862546.
Breslin S (Februar 2007). »Cytokine-release syndrome: overview and nursing implications«. Clinical Journal of Oncology Nursing. 11 (1 Suppl): 37–42. doi:10.1188/07.CJON.S1.37-42. PMID 17471824. S2CID 35773028.